Added to YB: 2026-05-12
Pitch date: 2026-05-10
BEAM [neutral]
Beam Therapeutics Inc.
Author Info
No bio for this author
Company Info
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.
Market Cap
$3.2B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-35.98
P/E
-50.32
EV/Sales
13.76
Sector
Biotechnology
Category
growth
Q1 Earnings Wire May 8, 2026 PM Drop - Beam Therapeutics Inc.
BEAM (earnings): Q1 loss $94.3M; $1.2B cash (runway to mid-2029). Risto-cel SCD BLA submission targeting YE 2026. BEAM-302 AATD pivotal cohort starts 2H26 w/ 60mg dose (~50 pts). BEAM-304 PKU IND in 2026. BEAM-301 GSDIa initial data 2026. Funded through all key catalysts; SCD launch near-term gate, AATD bigger long-term shot.
Read full article (1 min)